Patents by Inventor De-Kuan Chang

De-Kuan Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240115697
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Application
    Filed: June 22, 2023
    Publication date: April 11, 2024
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
    Patent number: 11723973
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: August 15, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
    Patent number: 11471490
    Abstract: Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 18, 2022
    Assignee: Torque Therapeutics, Inc.
    Inventors: Thomas L. Andresen, De-Kuan Chang, Douglas S. Jones, Jesse Lyons, Jonathan D. Nardozzi, Ulrik B. Nielsen, Michael Feldhaus
  • HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210000950
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Application
    Filed: June 2, 2020
    Publication date: January 7, 2021
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Immunostimulatory Fusion Molecules and Uses Thereof
    Publication number: 20200330514
    Abstract: Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.
    Type: Application
    Filed: July 3, 2018
    Publication date: October 22, 2020
    Inventors: Thomas L. Andresen, De-Kuan Chang, Douglas S. Jones, Jesse Lyons, Jonathan D. Nardozzi, Ulrik B. Nielsen
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200261578
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor) Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: November 4, 2019
    Publication date: August 20, 2020
    Inventors: Wayne A. Marasco, Chen Xu, De-Kuan Chang
  • Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
    Patent number: 10675349
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: June 9, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
    Patent number: 10463732
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Chen Xu, De-Kuan Chang
  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20190276544
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: December 17, 2018
    Publication date: September 12, 2019
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20180094064
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 5, 2018
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170304444
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: October 5, 2015
    Publication date: October 26, 2017
    Inventors: Wayne A. MARASCO, Chen XU, De-Kuan CHANG
  • HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170290911
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 12, 2017
    Inventors: Wayne A. MARASCO, Quan ZHU, De-Kuan CHANG
  • Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
    Patent number: 9587028
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 7, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
    Patent number: 9441045
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: September 13, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20160185865
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: August 7, 2015
    Publication date: June 30, 2016
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
    Publication number: 20150118153
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Application
    Filed: May 6, 2013
    Publication date: April 30, 2015
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang
  • Lung cancer-targeted peptides and applications thereof
    Patent number: 8415453
    Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 9, 2013
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Han-Chung Wu, Chin-Tarng Lin, De-Kuan Chang
  • Tumor-targeting peptides and uses thereof
    Patent number: 8394758
    Abstract: Tumor targeting peptides and uses thereof in tumor diagnosis and treatment.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: March 12, 2013
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, De-Kuan Chang, Chien-Yu Chiu
  • Tumor-Targeting Peptides and Uses Thereof
    Publication number: 20100119444
    Abstract: Tumor targeting peptides and uses thereof in tumor diagnosis and treatment.
    Type: Application
    Filed: October 28, 2009
    Publication date: May 13, 2010
    Applicant: Academia Sinica
    Inventors: Han-Chung Wu, De-Kuan Chang, Chien-Yu Chiu
  • Lung cancer-targeted peptides and applications thereof
    Publication number: 20080193375
    Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.
    Type: Application
    Filed: April 13, 2007
    Publication date: August 14, 2008
    Inventors: Han-Chung Wu, Chin-Tarng Lin, De-Kuan Chang